SCHEMBL984145

SCHEMBL984145

Nc1ncc(Br)cc1-c1nnsc1-c1cccc(Cl)c1F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP7 Q93009 1/20 0.34
MET P08581 1/20 0.32
KMO O15229 1/20 0.32
KMT2A Q03164 2/20 0.31
MEN1 O00255 1/20 0.31
HTT P42858 1/20 0.31
HSP90AA1 P07900 2/20 0.31
HSP90AB1 P08238 2/20 0.31
EPHB4 P54760 1/20 0.31
CYP2D6 P10635 1/20 0.30
MAOA P21397 1/20 0.30
MAPK1 P28482 1/20 0.30
ADRA1A P35348 1/20 0.30
SCN4A P35499 1/20 0.30
BLM P54132 1/20 0.30
PMP22 Q01453 1/20 0.30
PDE3A Q14432 1/20 0.30
SCN5A Q14524 1/20 0.30
SCN9A Q15858 1/20 0.30
SCN2A Q99250 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL982354 0.88 MAPK1 (0.39) USP7KMT2AMEN1HTTHSP90AA1
SCHEMBL984619 0.79 CHEK2 (0.40) USP7KMT2AMEN1HTTMAP4K4
SCHEMBL984931 0.76 HSP90AA1 (0.33) KMT2AMEN1HSP90AA1HSP90AB1CYP2D6
SCHEMBL984611 0.71 MAPK1 (0.37) USP7KMT2AMEN1HTTEPHB4
SCHEMBL11946789 0.70 FYN (0.46) USP7MEN1EPHB4CYP2D6MAOA
SCHEMBL11946787 0.68 PTPN11 (0.41) USP7KMT2AHTTEPHB4CYP2D6
SCHEMBL982287 0.68 GABRA1 (0.38) USP7METKMT2AMEN1
SCHEMBL985336 0.67 HCAR1 (0.37) USP7METKMT2AMEN1MAPK1
SCHEMBL982171 0.67 KCNN4 (0.46)
SCHEMBL986016 0.67 KCNN4 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101479255-B C-MET protein kinase inhibitors for the treatment of proliferative disorders VERTEX PHARMA 2013-05-01 CN disclosed
US-8232406-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-31 US disclosed
US-20110059936-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-10 US disclosed
US-7872031-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-18 US disclosed
EP-2004625-B1 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS VERTEX PHARMA (US) 2009-12-30 EP disclosed
CN-101479255-A c-MET protein kinase inhibitors for the treatment of proliferative disorders VERTEX PHARMA (US) 2009-07-08 CN disclosed
US-20070254868-A1 C-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059936-A1 C-MET PROTEIN KINASE INHIBITORS MET, PRKCH, ABL1 USP7 2086/4885MET 1/4885KMO 3848/4885
US-20070254868-A1 C-MET protein kinase inhibitors MET, PRKCH, ABL1 USP7 2086/4885MET 1/4885KMO 3848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.